EA Pharma

Stories

Upacicalcet meets primary endpoint in two Phase 3 trials for dialysis patients

Discovered upacicalcet; sells it in Japan as Upasita and partners with Pathalys on US development

Nearly all dialysis patients develop secondary hyperparathyroidism, a condition where parathyroid hormone rises out of control and raises the risk of bone fractures and heart disease. On October 23, Pathalys Pharma reported that its intravenous drug upacicalcet cut parathyroid hormone by at least 30% in 42% of treated patients, against 17% on placebo, in two identical Phase 3 trials.

Updated Nov 2